

In accordance with Sections 18-25 of Chapter 30A of the Massachusetts General Laws, Chapter 20 of the Acts of 2021, and Chapter 2 of the Acts of 2025, notice is hereby given of a meeting of the Massachusetts Commission on Step Therapy Protocols. The meeting will take place as noted below.

Massachusetts Division of Insurance

PUBLIC NOTICE: MEETING OF THE COMMISSION ON STEP THERAPY PROTOCOLS

Thursday, April 17 at 10 A.M. Remote Commissioner participation via Teams

The public can access the meeting via the following link: [Join the meeting now](#)

AGENDA

1. Introduction to the Commission on Step Therapy Protocols (“Commission”), chaired by the Division of Insurance, which has been formed to monitor the activities of step therapy processes used by Massachusetts insurance carriers in the review of pharmaceutical benefits, according to the provisions of Massachusetts law:

<https://malegislature.gov/Laws/SessionLaws/Acts/2022/Chapter254> (“Statute”).

2. Introduction to the membership of the Commission, including, as follows:

(i) Kevin Beagan, designee of Insurance Commissioner Michael Caljouw and chair of the Commission;

(ii) Nancy Ryan, designee of Executive Director David Seltz of the Health Policy Commission;

(iii) Kimberly Lenz, designee of Assistant Secretary for MassHealth Michael Levine;

(iv) Caitlin Sullivan, designee of Executive Director Lauren Peters of the Center for Health Information and Analysis;

(v) Cheryl Bartlett, a representative of the Massachusetts Public Health Association;

(vi) Paul Jones, a representative of Blue Cross and Blue Shield of Massachusetts, Inc.;

(vii) Sarah Chiaramida, a representative of the Massachusetts Association of Health Plans, Inc.;

(viii) Marc Hymovitz, a representative of a patient advocacy organization;

(ix) Eileen McAnneny, a representative of an employer organization;

(x) Clinton Pong, a licensed physician in the commonwealth; and

(xi) Darlene Sawicki, CNP, a licensed clinician, other than a physician, who has prescribing authority under the scope of her license.

3. Organization of the meeting and the Commission going forward, including but not limited to, discussion of scheduling of the following topics referenced within the Statute:

(i) analyze the impact of step therapy protocols on total medical expenses, health care quality outcomes, premium cost and out-of-pocket costs to the consumer and the health care cost benchmark; and

(ii) assess the efficacy of the step therapy exception process in ensuring that consumers diagnosed with medical conditions that rely on stability or have achieved a positive clinical response on a medication are able to maintain that course of treatment including, but not limited to, a form of multiple sclerosis. The commission shall also examine any available empirical data on the impact of step therapy protocols on health disparities related to outcomes, access, and medication adherence; and

(iii) produce a report to submit to the secretary of health and human services and the joint committee on health care financing by October 1 in even-numbered years.

4. Other Business and Adjournment